AGI.do

Products

What will AGI do for Afurolol?

This classification denotes a beta-adrenergic blocking agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WQ1WRV49R9. European Medicines Agency schedules Afurolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05283MIG. Afurolol generally arises in the molecular formula C15H21NO4. The term AFUROLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, no. 10 1979, list 19.) AFUROLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, AFUROLOL remains the US FDA Preferred Term for this commodity. Afurolol bears US NLM identifiers UMLS ID C2348000 and NCI Concept Code C72970. SMILES: O(CC(O)CNC(C)(C)C)C1C2C(COC2=O)CCC1.

How AGI delivers it

Four ways AGI delivers for Afurolol

  • Headless SaaS for Agents

    Give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

    For Afurolol, give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

  • Services-as-Software

    Get the professional outcome delivered as software, priced on results, not headcount.

    For Afurolol, get the professional outcome delivered as software, priced on results, not headcount.

Go deeper

Explore Afurolol

Read the deeper take on agi.asView as markdown